BCM
OPRX icon

BlueCrest Capital Management’s OptimizeRx OPRX Stock Holding History

BlueCrest Capital Management’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,690
Closed -$174K – 864
2019
Q1 		$174K Buy
13,690
+3,100
+29% +$40.3K 0.01% 982
2018
Q4 		$116K Buy
+10,590
New +$157K 0.01% 743

Other funds holding OPRX

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

BlueCrest Capital Management's OPRX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of OptimizeRx (OPRX) in Q2 2019, closing a stake of 13,690 shares — an estimated $174K sold.

BlueCrest Capital Management first reported a position in OPRX in Q4 2018 and held it in 2 quarters. The position peaked at $174K in Q1 2019. 56 funds tracked by Wall St. Rank hold OPRX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining OptimizeRx position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 13,690 OptimizeRx shares in Q2 2019, an estimated $174K.
  • BlueCrest Capital Management first reported a position in OptimizeRx in Q4 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's OptimizeRx position peaked at $174K in Q1 2019.
  • 56 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.